Johanna Bendell, MD
Medical Oncologist
Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma
Biological Therapy/Immunotherapy Chemotherapy Gene Therapy Pain Management Photodynamic Therapy Targeted Therapy
University of Chicago Pritzker
Medical School
Brigham and Women's Hospital
Residency
Brigham and Women's Hospital
Fellowship
American Board of Internal Medicine - Oncology
TN State Medical License: 2008 - 2017
American Board of Internal Medicine: Medical Oncology
Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody.
Dominguez, G.,Condamine, T. C.,Mony, S.,Hashimoto, A.,Wang, F.,Liu, Q.,Forero, A.,Bendell, J. C.,Witt, R.,Hockstein, N.,Kumar, P.,Gabrilovich, D.; Clin. Cancer Res.. 2016 Dec 15.
See more >>A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
Grilley-Olson JE, Bedard PL, Fasolo A, Cornfeld M, Cartee L, Razak ARA, Stayner L, Wu Y, Greenwood R, Singh R, Lee CB, Bendell J, Burris HA, Del Conte G, Sessa C, Infa...; Invest New Drugs. 2016-12-01.
See more >>Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after ...
Moore M, Gill S, Asmis T, Berry S, Burkes R, Zbuk K, Alcindor T, Jeyakumar A, Chan T, Rao S, Spratlin J, Tang PA, Rothenstein J, Chan E, Bendell J, Kudrik F, Kauh J, T...; Ann. Oncol.. 2016-12-01.
See more >>